Osteoporosis | Treatment Algorithms: Claims Data Analysis | US | 2023
A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents like Amgen’s Prolia and Evenity as well as Radius Health’s Tymlos are reserved for high-risk patients, primarily because of their high prices. This report presents insight into the treatment of a disease in which brands compete for market share in the second and later lines of therapy and monotherapy is preferred.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
- How have Evenity and Tymlos been integrated into the treatment algorithm, and what is their source of business?
- What percentage of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of osteoporosis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Eli Lilly, Radius Health, Amgen.
Key drugs: Oral bisphosphonates, zoledronate, Prolia, teriparatide, Tymlos, Evenity.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
